[go: up one dir, main page]

MX2013007917A - Derivados fusionados de aminodihidrotiazina como inhibidores de beta secretasa. - Google Patents

Derivados fusionados de aminodihidrotiazina como inhibidores de beta secretasa.

Info

Publication number
MX2013007917A
MX2013007917A MX2013007917A MX2013007917A MX2013007917A MX 2013007917 A MX2013007917 A MX 2013007917A MX 2013007917 A MX2013007917 A MX 2013007917A MX 2013007917 A MX2013007917 A MX 2013007917A MX 2013007917 A MX2013007917 A MX 2013007917A
Authority
MX
Mexico
Prior art keywords
secretasa
fusionated
aminodihydrotiazine
inhibitors
beta
Prior art date
Application number
MX2013007917A
Other languages
English (en)
Inventor
Jose Luis Castro Pineiro
Adrian Hall
Christopher Neil Farthing
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43769479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013007917(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2013007917A publication Critical patent/MX2013007917A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un derivado fusionado de aminodihidrotiazina de fórmula (I): (Ver Formula) En donde: X es hidrógeno o flúor; A es CH o N; Y es metilo, etilo, monofluorometilo, difluorometilo, trifluorometilo, difluoroetilo, metoxi, etoxi, metoximetilo o-C=N; y sales farmacéuticamente aceptables del mismo; compuesto que tiene un efecto inhibidor de la producción de A o un efecto inhibidor de la BACE1 y es útil como un agente profiláctico o terapéutico para una enfermedad neurodegenerativa causada por Aß y caracterizada por demencia tipo Alzheimer.
MX2013007917A 2011-01-21 2012-01-20 Derivados fusionados de aminodihidrotiazina como inhibidores de beta secretasa. MX2013007917A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1101140.0A GB201101140D0 (en) 2011-01-21 2011-01-21 Fused aminodihydrothiazine derivatives
PCT/EP2012/050833 WO2012098213A1 (en) 2011-01-21 2012-01-20 Fused aminodihydrothiazine derivatives useful as bace inhibitors

Publications (1)

Publication Number Publication Date
MX2013007917A true MX2013007917A (es) 2013-08-29

Family

ID=43769479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007917A MX2013007917A (es) 2011-01-21 2012-01-20 Derivados fusionados de aminodihidrotiazina como inhibidores de beta secretasa.

Country Status (22)

Country Link
US (3) US8338407B2 (es)
EP (1) EP2665732B1 (es)
JP (1) JP5947815B2 (es)
KR (1) KR101906466B1 (es)
CN (1) CN103328486B (es)
AR (1) AR084903A1 (es)
AU (1) AU2012208526B2 (es)
BR (1) BR112013018602A2 (es)
CA (1) CA2828738A1 (es)
CL (1) CL2013002083A1 (es)
ES (1) ES2575914T3 (es)
GB (1) GB201101140D0 (es)
IL (1) IL226596A (es)
MX (1) MX2013007917A (es)
PE (1) PE20141182A1 (es)
PH (1) PH12013501085A1 (es)
RU (1) RU2593756C2 (es)
SG (1) SG190908A1 (es)
TW (1) TW201309710A (es)
UA (1) UA109927C2 (es)
WO (1) WO2012098213A1 (es)
ZA (1) ZA201303801B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
CN101910143B (zh) 2008-01-18 2013-08-21 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
CN102119161B (zh) 2008-06-13 2015-07-08 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
JP5993875B2 (ja) 2011-01-21 2016-09-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
EP3718547A1 (en) * 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
WO2014039630A2 (en) * 2012-09-05 2014-03-13 Emory University Diagnostic testing in dementia and methods related thereto
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Ｂａｃｅ抑制劑
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JP2018508544A (ja) * 2015-03-19 2018-03-29 イーライ リリー アンド カンパニー 選択的ｂａｃｅ１阻害剤
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
KR20170108203A (ko) * 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
TW201740954A (zh) * 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
CN109641052A (zh) * 2016-08-18 2019-04-16 伊莱利利公司 BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
WO2018112094A1 (en) 2016-12-15 2018-06-21 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
MA54101A (fr) * 2016-12-15 2021-10-27 Amgen Inc Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
CA3047286A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
MX386618B (es) 2016-12-15 2025-03-19 Amgen Inc Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
AU2017376444B2 (en) 2016-12-15 2021-09-30 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
CN116143621A (zh) * 2022-12-14 2023-05-23 湖南农业大学 一种硼盐催化激活酰胺用于制备苯甲酸酯类化合物的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235551A (en) 1966-02-15 Novel derivatives of
US3227713A (en) 1966-01-04 Azine derivatives
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
US6642237B1 (en) 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
EP1507765A4 (en) 2002-05-03 2006-11-02 Israel Inst Biolog Res METHODS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND RELATED COMPOUNDS
AU2003254844A1 (en) 2002-08-09 2004-02-25 Takeda Chemical Industries, Ltd. Substituted amino compounds and use thereof
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
CA2505098A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005058311A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007530696A (ja) 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
CN101084199A (zh) 2004-10-15 2007-12-05 阿斯利康(瑞典)有限公司 取代的氨基化合物及其用途
EP1802588A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
JP2008526999A (ja) 2005-01-19 2008-07-24 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン
AU2006259572A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
EP2004630A4 (en) 2006-04-05 2010-05-19 Astrazeneca Ab 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
WO2007139230A1 (ja) 2006-05-31 2007-12-06 Asubio Pharma Co., Ltd. ７員環化合物並びにその製造法および医薬用途
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
CN101910143B (zh) * 2008-01-18 2013-08-21 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
KR20110003347A (ko) 2008-04-22 2011-01-11 쉐링 코포레이션 Ｂａｃｅ-1 억제제로서의 페닐-치환된 2-이미노-3-메틸 피롤로 피리미디논 화합물, 조성물 및 이의 용도
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
CN102119161B (zh) 2008-06-13 2015-07-08 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CA2738150A1 (en) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AU2010223937B2 (en) 2009-03-13 2015-01-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
MX2012015135A (es) 2010-07-01 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
JP5993875B2 (ja) 2011-01-21 2016-09-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物

Also Published As

Publication number Publication date
GB201101140D0 (en) 2011-03-09
US8940734B2 (en) 2015-01-27
RU2013138717A (ru) 2015-02-27
CL2013002083A1 (es) 2013-12-06
PH12013501085A1 (en) 2017-10-25
US20120190672A1 (en) 2012-07-26
AU2012208526A1 (en) 2013-05-02
JP5947815B2 (ja) 2016-07-06
NZ611365A (en) 2015-04-24
IL226596A (en) 2016-04-21
CA2828738A1 (en) 2012-07-26
ES2575914T3 (es) 2016-07-04
US8338407B2 (en) 2012-12-25
SG190908A1 (en) 2013-07-31
RU2593756C2 (ru) 2016-08-10
BR112013018602A2 (pt) 2020-09-01
WO2012098213A1 (en) 2012-07-26
CN103328486A (zh) 2013-09-25
AU2012208526B2 (en) 2015-09-24
EP2665732B1 (en) 2016-03-30
CN103328486B (zh) 2016-08-17
UA109927C2 (ru) 2015-10-26
US20140142091A1 (en) 2014-05-22
AR084903A1 (es) 2013-07-10
ZA201303801B (en) 2014-07-30
KR20140002724A (ko) 2014-01-08
US20130203740A1 (en) 2013-08-08
TW201309710A (zh) 2013-03-01
PE20141182A1 (es) 2014-09-14
EP2665732A1 (en) 2013-11-27
JP2014502987A (ja) 2014-02-06
KR101906466B1 (ko) 2018-10-10
US8592408B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
MX2013007917A (es) Derivados fusionados de aminodihidrotiazina como inhibidores de beta secretasa.
MX2013008255A (es) Derivados de aminodihidrotiazina fusionada.
CA2875877C (en) Syk inhibitors
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX347459B (es) Nuevos compuestos y composiciones para la inhibición de nampt.
MA38050A1 (fr) Inhibiteurs de gdf-8
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
JO3221B1 (ar) مركبات حمض داي ميثيل - بنزويك مفيدة لعلاج الحالات الالتهابية
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CR20130369A (es) Novedosos derivados heterocíclicos
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
GB201100181D0 (en) Fused aminodihydrothiazine derivatives
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JO3387B1 (ar) مشتقات بيتولين
MX2010001837A (es) Derivados de 4-pirimidinasulfamida.
CO7151507A2 (es) Compuestos de fenoxietil piperidina
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
AR082881A1 (es) Proceso para preparar un derivado de piperidina, intermediario para sintetizar un medicamento
EA201391524A1 (ru) Производные гликозида и их применение
IN2014DN05972A (es)
EA201290165A1 (ru) Способ получения производного фенилаланина
EA201391206A1 (ru) Способы синтеза производных предшественника молибдоптерина z
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
BR112016009811A2 (pt) derivado de carboximetil piperidina

Legal Events

Date Code Title Description
FG Grant or registration